Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis
Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis
复制标题
DOI：
10.2217/imt-2018-0086
复制
发表时间：
2019-02-01
期刊：
影响因子：
2.8
通讯作者：
Jafri, Syed
中科院分区：
文献类型：
--
作者：
El-Osta, Hazem;Jafri, Syed
目的：在这项荟萃分析中，我们评估了转移性非小细胞肺癌(NSCLC)中单药免疫检查点抑制剂(ICIS)疗效的几个预测因素。患者与方法：采用随机效应模型，根据年龄、性别、吸烟史、PD-L1状态和中枢神经系统受累程度评价ICIS与化疗的疗效比较。结果：共纳入8个随机试验。与化疗相比，ICIS在吸烟者、男性和PD-L1阳性亚组中显示出显著的无进展生存(PFS)优势。不吸烟者是ICIS的不利因素。女性和PD-L1不表达的患者在ICIS和化疗中表现出相似的PFS。ICI的PFS收益不受年龄或中枢神经系统受累的影响。ICIS的总体生存(OS)益处在所有亚组中都是一致的，除了从不吸烟的人。结论：男性、经常吸烟者和PD-L1阳性提示转移性非小细胞肺癌患者ICIS的发生。
Aim: In this meta-analysis, we evaluated several predictors of benefit to single-agent immune checkpoint inhibitors (ICIs) in metastatic non-small-cell lung cancer (NSCLC). Patients & methods: Using the random-effect model, we assessed the comparative efficacy of ICIs over chemotherapy according to age, gender, smoking history, PD-L1 status and CNS involvement. Results: Eight randomized trials were selected. In comparison to chemotherapy, ICIs demonstrated significant progression-free survival (PFS) superiority in ever-smoker, male and PD-L1 positive subgroups. Never-smoker was an unfavorable factor for ICIs. Female and PD-L1 nonexpressing patients demonstrated similar PFS between ICIs and chemotherapy. ICI's PFS benefit wasn't influenced by age or CNS involvement. The overall survival (OS) benefit of ICIs was consistent across all subgroups, except for never-smokers. Conclusion: Male, ever-smoker and positive PD-L1 are indicative of benefit to ICIs in metastatic non-small-cell lung cancer.